Research on amyloid, tau, and neurodegeneration (ATN) biomarkers, in accordance with the NIA-AA 2018 framework [1], has focused on tracking AD progression through beta-amyloid (A\documentclass[12pt]{minimal}\usepackage{amsmath}\usepackage{wasysym}\usepackage{amsfonts}\usepackage{amssymb}\usepackage{amsbsy}\usepackage{mathrsfs}\usepackage{upgreek}\setlength{\oddsidemargin}{-69pt}\begin{document}$$\beta$$\end{document}β) and Tau protein accumulations. The gene discussed is MAPT; the disease is Alzheimer disease.